Skip to main content
. 2021 Jun 11;12:693314. doi: 10.3389/fimmu.2021.693314

Figure 1.

Figure 1

Study design and workflow of the present study. (A) Four databases of gastric cancer sequencing or gene array data were used as test and validation cohorts. (B) RNA expression data were quantified with 29 immune signatures by single-sample Gene Set Enrichment Analysis (ssGSEA) and hierarchically clustered into three subtypes. (C) Clinical features, genetic and epigenetic patterns, immune characteristics, and enriched pathways were compared among the three subtypes. In addition, an association between subtypes and responses to immunotherapy (pembrolizumab) was evaluated in the PRJEB25780 cohort.